LA
LADX.US LadRx Corporation
- Market cap
- USD 148.00
- P/E
- -
- P/B
- 3.61x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2025.
Is LADX.US undervalued?
Graham numberThe Graham number of LadRx Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LadRx Corporation fundamental analysis
No fundamental analysis for LadRx Corporation yet.
LadRx Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LadRx Corporation
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives o…
Full company profileLadRx Corporation financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
LadRx Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 250K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -8.25M | -7.86M | -6.83M | -5.98M | -4.56M | -3.82M | -3.62M | -2.88M |
| EBITDA | -7.33M | -7.50M | -6.60M | -5.97M | -4.55M | -3.81M | -3.62M | -2.88M |
| Net Income | -12.7M | -7.16M | -6.70M | -13.2M | -4.20M | 400K | -1.59M | -2.88M |
| EPS | -0.38 | -0.21 | -0.18 | -0.34 | -0.09 | 0.81 | -3.21 | -5.81 |
| Balance Sheet | ||||||||
| Total Assets | 22.9M | 17.3M | 12.1M | 8.73M | 2.25M | 2.31M | 840K | 260K |
| Total Liabilities | 2.56M | 2.05M | 3.19M | 3.95M | 2.22M | 2.20M | 2.26M | 2.39M |
| Shareholders' Equity | 20.4M | 15.2M | 8.87M | 4.78M | 25.7K | 107K | -1.42M | -2.13M |
| Cash & Short-term Investments | 21.4M | 16.1M | 10.0M | 6.77M | 1.37M | 2.07M | 760K | 207K |
| Cash Flow | ||||||||
| Operating Cash Flow | -10.9M | -5.72M | -6.14M | -12.3M | -4.83M | 1.01M | -1.31M | -2.21M |
| Capital Expenditure | 11.5K | 24.7K | 25.9K | 7.00K | 766.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -10.9M | -5.74M | -6.17M | -12.3M | -4.83M | 1.01M | -1.31M | -2.21M |
| Ratios | ||||||||
| ROE | -62.4% | -47.1% | -75.5% | -275.9% | -16,331.9% | 373.0% | - | - |
| ROA | -55.5% | -41.5% | -55.6% | -151.0% | -187.0% | 17.4% | -189.4% | -1,106.3% |
| Net Profit Margin | -5,085.4% | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
LadRx Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | USD 68.8K | 0.14 | 17.2% |
| 2022 | USD 561K | 0.01 | - |
| 2021 | USD 172K | 0.00 | - |
| 2020 | USD 172K | 0.00 | - |
| 2019 | USD 172K | 0.01 | - |
| 2018 | USD 172K | 0.01 | - |
| 2016 | - | - | - |
| 2015 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:100 on May 17, 2023.
Who owns LadRx Corporation
- Insiders 0.68%
- Institutions 0.00%
- Public & others 99.32%
- Shares outstanding 495K
- Free float 492K
LadRx Corporation company profile
- Company name
- LadRx Corporation
- Ticker
- LADX.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 11726 San Vicente Boulevard, Los Angeles, CA, United States, 90049
- Phone
- 310 826 5648
- Website
- ladrxcorp.com
About LadRx Corporation
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer. In addition, the company develops albumin companion diagnostic (ACDx) to identify patients with cancer that benefits from treatment with the four LADR lead candidates. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. The company was incorporated in 1985 and is headquartered in Los Angeles, California.
LadRx Corporation management
2- Mr. John Y. Caloz CPATreasurer, Senior VP & Corporate Secretary · born 1952
- Molly Carey PoarchGlobal & U.S. Head of Corporate Communications